57489-77-7Clc1cc(Cl)n2nccc2n1JMTFWCYVZOFHLR-UHFFFAOYSA-N57489-77-7DTXSID50454231CHEMBL3747320Danger
H301 (33.3%): Toxic if swallowed [Danger Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P272, P280, P301+P316, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Uses5,7-Dichloropyrazolo[1,5-a]pyrimidine is a pharmaceutical intermediate compound that can be used in a palladium-catalysed pharmaceutical synthesis cross-coupling reaction. 2,4-Dichloroquinoline reacts with benzylzinc and phenylzinc reagents in the presence of catalytic quantities of palladium complexes to yield only α-substituted products.2,4-Dichloroquinolines have been found to react with benzylzinc and phenylzinc reagents in catalytic amounts of palladium compounds to produce only α-substituted products. LiCl was found to be an effective additive for γ-selective coupling reactions. These α- or γ-selective coupling conditions are applicable to the reaction of 5,7-Dichloropyrazolo[1,5-a]pyrimidine and biphenylmethyl zinc reagents in the synthesis of angiotensin II receptor antagonists. This regioselectivity should be generally applicable to other α,γ-dichloropyrazine systems[1].
Loading…